Securitization of Pharmaceutical Royalties: A Prescription for Market Growth

February 02, 2011
Like the rest of the securitization industry, royalty-based securitizations suffered a period of retrenchment following the collapse of the credit markets in 2008 and 2009. Now, with the return of some degree of normalcy to the financial markets, royalty-based securitizations have staged something of a come-back, with both single-asset and diversified structures returning to the market. This update provides an overview of recent trends and challenges faced in the pharmaceutical royalties securitization area.